Find Duloxetine Hydrochloride manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 136434-34-9, Duloxetine hcl, Cymbalta, (s)-duloxetine hydrochloride, Ariclaim, Xeristar
Molecular Formula
C18H20ClNOS
Molecular Weight
333.9  g/mol
InChI Key
BFFSMCNJSOPUAY-LMOVPXPDSA-N
FDA UNII
9044SC542W

Duloxetine Hydrochloride
A thiophene derivative and selective NEUROTRANSMITTER UPTAKE INHIBITOR for SEROTONIN and NORADRENALINE (SNRI). It is an ANTIDEPRESSIVE AGENT and ANXIOLYTIC, and is also used for the treatment of pain in patients with DIABETES MELLITUS and FIBROMYALGIA.
1 2D Structure

Duloxetine Hydrochloride

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine;hydrochloride
2.1.2 InChI
InChI=1S/C18H19NOS.ClH/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16;/h2-10,13,17,19H,11-12H2,1H3;1H/t17-;/m0./s1
2.1.3 InChI Key
BFFSMCNJSOPUAY-LMOVPXPDSA-N
2.1.4 Canonical SMILES
CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32.Cl
2.1.5 Isomeric SMILES
CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32.Cl
2.2 Other Identifiers
2.2.1 UNII
9044SC542W
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Cymbalta

2. Duloxetine

3. Duloxetine Ethanedioate (1:1), (+-)-isomer - T353987

4. Duloxetine Hcl

5. Duloxetine, (+)-isomer

6. Hcl, Duloxetine

7. Hydrochloride, Duloxetine

8. Ly 227942

9. Ly 248686

10. Ly-227942

11. Ly-248686

12. Ly227942

13. Ly248686

14. N-methyl-3-(1-naphthalenyloxy)-2-thiophenepropanamine

15. N-methyl-3-(1-naphthalenyloxy)-3-(2-thiophene)propanamide

2.3.2 Depositor-Supplied Synonyms

1. 136434-34-9

2. Duloxetine Hcl

3. Cymbalta

4. (s)-duloxetine Hydrochloride

5. Ariclaim

6. Xeristar

7. (s)-n-methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine Hydrochloride

8. Duloxetine Hydrochloride [usan]

9. Duloxetine Mylan

10. Duloxetine (hydrochloride)

11. Ly248686 Hcl

12. Ly-248686 Hcl

13. Nsc-759112

14. Cpd000469136

15. Duloxetine (as Hydrochloride)

16. Chebi:31526

17. (3s)-n-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine;hydrochloride

18. 9044sc542w

19. Yentreve (tn)

20. (+)-(s)-n-methyl-gamma-(1-naphthyloxy)-2-thiophenepropylamine Hydrochloride

21. Dsstox_cid_26443

22. Dsstox_rid_81618

23. Dsstox_gsid_46443

24. Duloxetine Boehringer Ingelheim

25. Methyl[3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propyl]amine Hydrochloride

26. (+)-(s)-n-methyl-.gamma.-(1-naphthyloxy)-2-thiophenepropylamine Hydrochloride

27. (s)-n-methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine Hcl

28. Smr000469136

29. Dulane 20

30. Cas-136434-34-9

31. Ncgc00164559-01

32. C18h19nos.hcl

33. Unii-9044sc542w

34. Ly 248686 Hcl

35. Cymbalta (tn)

36. Duloxetina Cloridrato

37. Duloxetine Hydrochlorise

38. Duloxetine Lilly

39. Cloridrato De Duloxetina

40. Clorhidrato De Duloxetina

41. Chlorhydrate De Duloxetine

42. Duloxetine Hcl (cymbalta)

43. Mls001401452

44. Mls006010054

45. (s)-duloxetine (hydrochloride)

46. Duloxetine Hydrochloride- Bio-x

47. Chembl1200328

48. Dtxsid9046443

49. Duloxetine Hydrochloride Solution

50. Duloxetine For System Suitability

51. Hy-b0161a

52. Pharmakon1600-01505387

53. Ly-248686 Hydrochloride

54. Amy12420

55. Duloxetine Hydrochloride (jan/usp)

56. Tox21_112188

57. Ac-924

58. Duloxetine Hydrochloride [mi]

59. Mfcd06407958

60. Nsc744012

61. Nsc759112

62. S2084

63. Duloxetine Hydrochloride [jan]

64. (3s)-n-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine Hydrochloride

65. Akos016340453

66. Tox21_112188_1

67. Ccg-101106

68. Cs-1993

69. Ks-1168

70. Nc00356

71. Nsc 759112

72. Nsc-744012

73. (3s)-n-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine Hydrochloride

74. 2-thiophenepropanamine, N-methyl-gamma-(1-naphthalenyloxy)-, Hydrochloride, (gammas)-

75. 2-thiophenepropanamine, N-methyl-gamma-(1-naphthalenyloxy)-, Hydrochloride, (s)-

76. Duloxetine Hydrochloride [mart.]

77. Duloxetine Hydrochloride [usp-rs]

78. Duloxetine Hydrochloride [who-dd]

79. Ncgc00164559-03

80. (s)-(+)-duloxetine Hydrochloride

81. Bd165546

82. Ly-264453

83. D-170

84. D4223

85. Sw197393-3

86. Duloxetine Hydrochloride [orange Book]

87. (s)-duloxetine Hydrochloride, >=98% (hplc)

88. D01179

89. Duloxetine Hydrochloride [ep Monograph]

90. Duloxetine Hydrochloride [usp Monograph]

91. 434d349

92. Q-102508

93. Duloxetine Hydrochloride 1.0 Mg/ml In Methanol (as Free Base)

94. (+)-(s)-n-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propanamine Hydrochloride

95. Duloxetine Hydrochloride, European Pharmacopoeia (ep) Reference Standard

96. (+)-(s)-n-methyl-3-(1-naphthyloxy)- 3-(2-thienyl)propanamine Hydrochloride

97. (3s)-n-methyl-3-(naphthalen-1-yloxy)-3-(2-thienyl)propan-1-amine Hydrochloride

98. (3s)-n-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amin Hydrochloride.

99. (gammas)-2-thiophenepropanamine, N-methyl-gamma-(1-naphthalenyloxy)hydrochloride (1:1)

100. (gammas)-n-methyl-gamma-(1-naphthalenyloxy)-2-thiophenepropanamine Hydrochloride

101. (s)-(+)-n-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl) Propanamine Hydrochloride

102. (s)-(+)-n-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine Hydrochloride

103. 2-thiophenepropanamine, N-methyl-.gamma.-(1-naphthalenyloxy)-, Hydrochloride, (s)-

104. Duloxetine For System Suitability, European Pharmacopoeia (ep) Reference Standard

105. Duloxetine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

106. Duloxetine Hydrochloride, United States Pharmacopeia (usp) Reference Standard

2.4 Create Date
2005-06-24
3 Chemical and Physical Properties
Molecular Weight 333.9 g/mol
Molecular Formula C18H20ClNOS
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count3
Rotatable Bond Count6
Exact Mass333.0954131 g/mol
Monoisotopic Mass333.0954131 g/mol
Topological Polar Surface Area49.5 Ų
Heavy Atom Count22
Formal Charge0
Complexity312
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Information
1 of 4  
Drug NameCymbalta
PubMed HealthDuloxetine (By mouth)
Drug ClassesAntidepressant, Central Nervous System Agent, Neuropathic Pain Agent
Drug LabelCymbalta (Duloxetine Delayed-Release Capsules) is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) for oral administration. Its chemical designation is (+)-( )- -methyl--(1-naphthyloxy)-2-thiophenepropylamine hydrochloride. The e...
Active IngredientDuloxetine hydrochloride
Dosage FormCapsule, delayed rel pellets
Routeoral; Oral
Strengtheq 30mg base; eq 20mg base; eq 60mg base
Market StatusPrescription
CompanyLilly

2 of 4  
Drug NameDuloxetine hydrochloride
Drug LabelCymbalta (Duloxetine Delayed-Release Capsules) is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) for oral administration. Its chemical designation is (+)-( )- -methyl--(1-naphthyloxy)-2-thiophenepropylamine hydrochloride. The e...
Active IngredientDuloxetine hydrochloride
Dosage FormCapsule, delayed rel pellets; Capsule, delayed release
Routeoral; Oral
Strengtheq 40mg base; 60mg; 30mg; eq 30mg base; eq 20mg base; eq 60mg base; 20mg
Market StatusTentative Approval; Prescription
CompanyWockhardt; Actavis Elizabeth; Breckenridge Pharm; Apotex; Alembic Pharms; Teva Pharms Usa; Aurobindo Pharma; Torrent Pharms; Zydus Pharms Usa; Lupin; Dr Reddys Labs; Sandoz; Sun Pharma Global; Impax Labs

3 of 4  
Drug NameCymbalta
PubMed HealthDuloxetine (By mouth)
Drug ClassesAntidepressant, Central Nervous System Agent, Neuropathic Pain Agent
Drug LabelCymbalta (Duloxetine Delayed-Release Capsules) is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) for oral administration. Its chemical designation is (+)-( )- -methyl--(1-naphthyloxy)-2-thiophenepropylamine hydrochloride. The e...
Active IngredientDuloxetine hydrochloride
Dosage FormCapsule, delayed rel pellets
Routeoral; Oral
Strengtheq 30mg base; eq 20mg base; eq 60mg base
Market StatusPrescription
CompanyLilly

4 of 4  
Drug NameDuloxetine hydrochloride
Drug LabelCymbalta (Duloxetine Delayed-Release Capsules) is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) for oral administration. Its chemical designation is (+)-( )- -methyl--(1-naphthyloxy)-2-thiophenepropylamine hydrochloride. The e...
Active IngredientDuloxetine hydrochloride
Dosage FormCapsule, delayed rel pellets; Capsule, delayed release
Routeoral; Oral
Strengtheq 40mg base; 60mg; 30mg; eq 30mg base; eq 20mg base; eq 60mg base; 20mg
Market StatusTentative Approval; Prescription
CompanyWockhardt; Actavis Elizabeth; Breckenridge Pharm; Apotex; Alembic Pharms; Teva Pharms Usa; Aurobindo Pharma; Torrent Pharms; Zydus Pharms Usa; Lupin; Dr Reddys Labs; Sandoz; Sun Pharma Global; Impax Labs

4.2 Drug Indication

- Treatment of major depressive disorder;

- Treatment of diabetic peripheral neuropathic pain;

- Treatment of generalised anxiety disorder;

- Duloxetine Mylan is indicated in adults.


Duloxetine Lilly is indicated in adults for:

- Treatment of major depressive disorder

- Treatment of diabetic peripheral neuropathic pain

- Treatment of generalised anxiety disorder

Duloxetine Lilly is indicated in adults.


Yentreve is indicated for women for the treatment of moderate to severe stress urinary incontinence (SUI).


Treatment of major depressive disorder.

Treatment of diabetic peripheral neuropathic pain.

Treatment of generalised anxiety disorder.

Cymbalta is indicated in adults.


Treatment of diabetic peripheral neuropathic pain.

Ariclaim is indicated in adults.


Treatment of diabetic peripheral neuropathic pain in adults.


Treatment of chronic pain, Treatment of diabetic neuropathic pain, Treatment of generalised anxiety disorder, Treatment of major depressive disorder, Treatment of stress urinary incontinence


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Antidepressive Agents

Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. (See all compounds classified as Antidepressive Agents.)


Analgesics

Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)


Serotonin and Noradrenaline Reuptake Inhibitors

Drugs that selectively block or suppress the plasma membrane transport of SEROTONIN and NORADRENALINE into axon terminals and are used as ANTIDEPRESSIVE AGENTS. (See all compounds classified as Serotonin and Noradrenaline Reuptake Inhibitors.)


Dopamine Agents

Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. (See all compounds classified as Dopamine Agents.)


5.2 FDA Pharmacological Classification
5.2.1 Pharmacological Classes
Serotonin Uptake Inhibitors [MoA]; Serotonin and Norepinephrine Reuptake Inhibitor [EPC]; Norepinephrine Uptake Inhibitors [MoA]
5.3 ATC Code

N06AX21


N06AX21


N06AX21


N06AX21


N06AX21


N06AX21


API SUPPLIERS

read-more
read-more

01

HRV Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHRV Pharma - Market Expansion Leader in Pharmaceuticals.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF AU, MX, ... arrow-down AUDIT
HRV Global Life Sciences

02

LGM Pharma

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
LGM Pharma CB

03

Evonik

Germany

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEvonik Health Care is the innovation hub for leading life science companies

Flag Germany
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF arrow-down VMF Others AUDIT arrow-down
Evonik company banner

04

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Metrochem

05

Dr. Reddy's Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

Product Not Available For Sales

USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT arrow-down
Dr Reddy Company Banner

06

Egis Pharmaceuticals PLC

Hungary

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothExpand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

Flag Hungary
Digital Content Digital Content
USDMF CEP/COS arrow-down JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Egis Pharmaceuticals

07

Jai Radhe Sales

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothJai Radhe Sales is your partner for all your sourcing needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Jai Radhe Sales

08

Moehs Iberica

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMoehs Group, a reference company in the production of pharmaceutical active ingredients.

Flag Spain
Digital Content Digital Content
USDMF arrow-down CEP/COS arrow-down JDMF arrow-down EU-WC NDC arrow-down KDMF arrow-down VMF ASMF arrow-down AUDIT arrow-down
Moehs Iberica

09

Tagoor Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Tagoor Laboratories

10

Tenatra Exports

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Tenatra
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMoehs Group, a reference company in the production of pharmaceutical active ingredients.

Flag Spain
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2022-04-15

Pay. Date : 2022-03-08

DMF Number : 36834

Submission : 2022-03-16

Status : Active

Type : II

Moehs Iberica

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSCI Pharmtech offers high-quality, cost-effective APIs, advanced intermediates, & custom products with global expertise and precision.

Flag Taiwan
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2013-07-23

Pay. Date : 2013-03-06

DMF Number : 24939

Submission : 2011-05-06

Status : Active

Type : II

SCI Company Banner

04

Vietnam Medi-Pharm Expo
Not Confirmed

04

Vietnam Medi-Pharm Expo
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2020-11-17

Pay. Date : 2020-11-10

DMF Number : 20996

Submission : 2007-10-30

Status : Active

Type : II

blank

05

Olon Spa

Italy

USDMF

arrow
Vietnam Medi-Pharm Expo
Not Confirmed

05

Olon Spa

Italy
arrow
Vietnam Medi-Pharm Expo
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 19974

Submission : 2006-11-03

Status : Inactive

Type : II

blank

06

Vietnam Medi-Pharm Expo
Not Confirmed

06

Vietnam Medi-Pharm Expo
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 21485

Submission : 2008-03-31

Status : Active

Type : II

blank

07

Vietnam Medi-Pharm Expo
Not Confirmed

07

Vietnam Medi-Pharm Expo
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2018-02-23

Pay. Date : 2018-02-09

DMF Number : 21478

Submission : 2008-03-29

Status : Active

Type : II

blank

08

Vietnam Medi-Pharm Expo
Not Confirmed

08

Vietnam Medi-Pharm Expo
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 21385

Submission : 2008-02-29

Status : Inactive

Type : II

blank

09

Cadila Healthcare Ltd

India

USDMF

arrow
Vietnam Medi-Pharm Expo
Not Confirmed

09

Vietnam Medi-Pharm Expo
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 19631

Submission : 2006-07-25

Status : Inactive

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

CEP/COS

read-more
read-moreread-more
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothExpand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

Flag Hungary
Digital Content Digital Content
CEP 2023-144 - Rev 00
Valid
Chemical
2024-12-19
2594
Egis Pharmaceuticals

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothExpand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

Flag Hungary
Digital Content Digital Content

Certificate Number : CEP 2023-144 - Rev 00

Status : Valid

Issue Date : 2024-12-19

Type : Chemical

Substance Number : 2594

Egis Pharmaceuticals
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMoehs Group, a reference company in the production of pharmaceutical active ingredients.

Flag Spain
Digital Content Digital Content
CEP 2012-319 - Rev 01
Valid
Chemical
2024-06-21
2594
Moehs Iberica

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMoehs Group, a reference company in the production of pharmaceutical active ingredients.

Flag Spain
Digital Content Digital Content

Certificate Number : CEP 2012-319 - Rev 01

Status : Valid

Issue Date : 2024-06-21

Type : Chemical

Substance Number : 2594

Moehs Iberica
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSCI Pharmtech offers high-quality, cost-effective APIs, advanced intermediates, & custom products with global expertise and precision.

Flag Taiwan
Digital Content Digital Content
R1-CEP 2012-217 - Rev 01
Valid
Chemical
2022-09-21
2594
SCI Company Banner

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSCI Pharmtech offers high-quality, cost-effective APIs, advanced intermediates, & custom products with global expertise and precision.

Flag Taiwan
Digital Content Digital Content

Certificate Number : R1-CEP 2012-217 - Rev 01

Status : Valid

Issue Date : 2022-09-21

Type : Chemical

Substance Number : 2594

SCI Company Banner

04

AMWC Asia-TDAC
Not Confirmed
arrow
arrow
AMWC Asia-TDAC
Not Confirmed

Certificate Number : R1-CEP 2013-016 - Rev 02

Status : Valid

Issue Date : 2021-07-26

Type : Chemical

Substance Number : 2594

blank

05

AMWC Asia-TDAC
Not Confirmed
arrow
arrow
AMWC Asia-TDAC
Not Confirmed

Certificate Number : R1-CEP 2014-239 - Rev 00

Status : Valid

Issue Date : 2020-08-28

Type : Chemical

Substance Number : 2594

blank

06

AMWC Asia-TDAC
Not Confirmed
arrow
arrow
AMWC Asia-TDAC
Not Confirmed

Certificate Number : R1-CEP 2015-166 - Rev 00

Status : Valid

Issue Date : 2021-10-22

Type : Chemical

Substance Number : 2594

blank

07

AMWC Asia-TDAC
Not Confirmed
arrow
arrow
AMWC Asia-TDAC
Not Confirmed

Certificate Number : R0-CEP 2013-197 - Rev 00

Status : Withdrawn by Holder

Issue Date : 2014-12-01

Type : Chemical

Substance Number : 2594

blank

08

AMWC Asia-TDAC
Not Confirmed
arrow
arrow
AMWC Asia-TDAC
Not Confirmed

Certificate Number : R1-CEP 2014-297 - Rev 00

Status : Valid

Issue Date : 2021-08-05

Type : Chemical

Substance Number : 2594

blank

09

AMWC Asia-TDAC
Not Confirmed
arrow
arrow
AMWC Asia-TDAC
Not Confirmed

Certificate Number : R1-CEP 2013-340 - Rev 00

Status : Valid

Issue Date : 2020-11-03

Type : Chemical

Substance Number : 2594

blank

10

AMWC Asia-TDAC
Not Confirmed
arrow
arrow
AMWC Asia-TDAC
Not Confirmed

Certificate Number : R0-CEP 2015-130 - Rev 01

Status : Expired

Issue Date : 2019-02-12

Type : Chemical

Substance Number : 2594

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.


Lead Product(s): Duloxetine Hydrochloride,Inapplicable

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 14, 2014

Dr Reddy Company Banner

01

Lead Product(s) : Duloxetine Hydrochloride,Inapplicable

Therapeutic Area : Undisclosed

Highest Development Status : Phase I

Partner/Sponsor/Collaborator : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

November 14, 2014

Dr Reddy Company Banner

Details:

Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.


Lead Product(s): Duloxetine Hydrochloride,Inapplicable

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 14, 2014

Dr Reddy Company Banner

02

Lead Product(s) : Duloxetine Hydrochloride,Inapplicable

Therapeutic Area : Undisclosed

Highest Development Status : Phase I

Partner/Sponsor/Collaborator : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

November 14, 2014

Dr Reddy Company Banner

Details:

ALA-3000 is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Depressive Disorder, Treatment-Resistant.


Lead Product(s): ALA-3000,Escitalopram Oxalate,Sertraline Hydrochloride,Duloxetine Hydrochloride,Venlafaxine

Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 11, 2025

blank

03

Vietnam Medi-Pharm Expo
Not Confirmed
Vietnam Medi-Pharm Expo
Not Confirmed

Details : ALA-3000 is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Depressive Disorder, Treatment-Resistant.

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Inapplicable

May 11, 2025

blank
  • Development Update

Details:

Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoarthritis, Knee.


Lead Product(s): Duloxetine Hydrochloride,Inapplicable

Therapeutic Area: Musculoskeletal Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 21, 2024

blank

04

Sunnybrook Health Sciences Centre

Country
arrow
Vietnam Medi-Pharm Expo
Not Confirmed

Sunnybrook Health Sciences Centre

Country
arrow
Vietnam Medi-Pharm Expo
Not Confirmed

Details : Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Osteoarthritis, Knee.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 21, 2024

blank
  • Development Update

Details:

Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.


Lead Product(s): Duloxetine Hydrochloride,Benztropine

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Miscellaneous

Sponsor: Central Denmark Region | University of Aarhus | Vejle Hospital | Aalborg University | TrygFonden | Independent Research Fund Denmark

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 30, 2024

blank

05

Aarhus University Hospital

Country
arrow
Vietnam Medi-Pharm Expo
Not Confirmed

Aarhus University Hospital

Country
arrow
Vietnam Medi-Pharm Expo
Not Confirmed

Lead Product(s) : Duloxetine Hydrochloride,Benztropine

Therapeutic Area : Undisclosed

Highest Development Status : Phase IV

Partner/Sponsor/Collaborator : Central Denmark Region | University of Aarhus | Vejle Hospital | Aalborg University | TrygFonden | Independent Research Fund Denmark

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

January 30, 2024

blank

Details:

Spravato® (esketamine) is the S-enantiomer of racemic ketamine and is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor. It is being developed for treating resistant major depressive disorder.


Lead Product(s): Esketamine Hydrochloride,Duloxetine Hydrochloride

Therapeutic Area: Psychiatry/Psychology Brand Name: Spravato

Study Phase: Approved FDFProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 23, 2022

blank

06

Vietnam Medi-Pharm Expo
Not Confirmed
Vietnam Medi-Pharm Expo
Not Confirmed

Details : Spravato® (esketamine) is the S-enantiomer of racemic ketamine and is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor. It is being developed for treating resistant major depressiv...

Product Name : Spravato

Product Type : Controlled Substance

Upfront Cash : Inapplicable

November 23, 2022

blank
  • Development Update

Details:

Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pain, Postoperative.


Lead Product(s): Duloxetine Hydrochloride,Inapplicable

Therapeutic Area: Neurology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 10, 2022

blank

07

Scripps Health

Country
arrow
Vietnam Medi-Pharm Expo
Not Confirmed

Scripps Health

Country
arrow
Vietnam Medi-Pharm Expo
Not Confirmed

Details : Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pain, Postoperative.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

November 10, 2022

blank

Details:

Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Osteoarthritis, Knee.


Lead Product(s): Duloxetine Hydrochloride,Etoricoxib,Omeprazole

Therapeutic Area: Musculoskeletal Brand Name: Undisclosed

Study Phase: UndisclosedProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 25, 2022

blank

08

Vietnam Medi-Pharm Expo
Not Confirmed
Vietnam Medi-Pharm Expo
Not Confirmed

Details : Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Osteoarthritis, Knee.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 25, 2022

blank

Details:

Citalopram HBr is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Depressive Disorder.


Lead Product(s): Citalopram Hydrobromide,Escitalopram Oxalate,Fluoxetine Hydrochloride,Paroxetine Hydrochloride,Sertraline Hydrochloride,Duloxetine Hydrochloride,Venlafaxine

Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Miscellaneous

Sponsor: National Institute of Mental Health | Partners in Health | Brigham and Women's Hospital | Malawi Ministry of Health | Blantyre College of Medicine | University of Birmingham

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 02, 2021

blank

09

Vietnam Medi-Pharm Expo
Not Confirmed
Vietnam Medi-Pharm Expo
Not Confirmed

Lead Product(s) : Citalopram Hydrobromide, Escitalopram Oxalate, Fluoxetine Hydrochloride, Paroxetine Hydrochloride, Sertraline Hydrochloride

Therapeutic Area : Psychiatry/Psychology

Highest Development Status : Phase IV

Partner/Sponsor/Collaborator : National Institute of Mental Health | Partners in Health | Brigham and Women's Hospital | Malawi Ministry of Health | Blantyre College of Medicine | University of Birmingham

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Citalopram HBr is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Depressive Disorder.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 02, 2021

blank

Details:

Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.


Lead Product(s): Duloxetine Hydrochloride,Inapplicable

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 12, 2021

blank

10

Andromaco

Chile
arrow
Vietnam Medi-Pharm Expo
Not Confirmed

Andromaco

Chile
arrow
Vietnam Medi-Pharm Expo
Not Confirmed

Details : Duloxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 12, 2021

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATE SUPPLIERS

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

CAS Number : 116539-55-0

End Use API : Duloxetine Hydrochloride

About The Company : Aarti Pharmalabs is generic APIs & Intermediates manufacturing company & small molecule drug substance CDMO and the largest Indian manufacturer of Xanthine Deri...

Aarti Industries Company Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.

CAS Number : 116539-55-0

End Use API : Duloxetine Hydrochloride

About The Company : Tagoor Laboratories, established in 2018 and part of the Tagoor Group, provides APIs, advanced intermediates, and key starting materials for critical and high-g...

Tagoor Laboratories

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothZeon Pharma is a manufacturer and supplier of APIs & Intermediates.

CAS Number : 13636-02-7

End Use API : Duloxetine Hydrochloride

About The Company : Zeon Pharma Industries India Pvt. Ltd. is an ISO 9001:2015, cGMP, and WHO-GMP certified company with a dedicated manufacturing facility for Bulk Drugs (APIs), p...

Zeon Pharma Industries India Pvt Ltd

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothZeon Pharma is a manufacturer and supplier of APIs & Intermediates.

CAS Number : 132335-44-5

End Use API : Duloxetine Hydrochloride

About The Company : Zeon Pharma Industries India Pvt. Ltd. is an ISO 9001:2015, cGMP, and WHO-GMP certified company with a dedicated manufacturing facility for Bulk Drugs (APIs), p...

Zeon Pharma Industries India Pvt Ltd

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothZeon Pharma is a manufacturer and supplier of APIs & Intermediates.

CAS Number : 116817-84-6

End Use API : Duloxetine Hydrochloride

About The Company : Zeon Pharma Industries India Pvt. Ltd. is an ISO 9001:2015, cGMP, and WHO-GMP certified company with a dedicated manufacturing facility for Bulk Drugs (APIs), p...

Zeon Pharma Industries India Pvt Ltd

06

Vietnam Medi-Pharm Expo
Not Confirmed
arrow
Vietnam Medi-Pharm Expo
Not Confirmed
arrow

CAS Number : 132335-44-5

End Use API : Duloxetine Hydrochloride

About The Company : Chemeca Drugs Private Limited was erstwhile M/s. Vegesna Laboratories Pvt Limited. M/s. Vegesna Laboratories Pvt Limited is a Private limited company having its...

blank

07

Vietnam Medi-Pharm Expo
Not Confirmed
arrow
Vietnam Medi-Pharm Expo
Not Confirmed
arrow

CAS Number : 132335-47-8

End Use API : Duloxetine Hydrochloride

About The Company : Chemeca Drugs Private Limited was erstwhile M/s. Vegesna Laboratories Pvt Limited. M/s. Vegesna Laboratories Pvt Limited is a Private limited company having its...

blank

08

Vietnam Medi-Pharm Expo
Not Confirmed
arrow
Vietnam Medi-Pharm Expo
Not Confirmed
arrow

CAS Number : 164071-56-1

End Use API : Duloxetine Hydrochloride

About The Company : Chemeca Drugs Private Limited was erstwhile M/s. Vegesna Laboratories Pvt Limited. M/s. Vegesna Laboratories Pvt Limited is a Private limited company having its...

blank

09

Vietnam Medi-Pharm Expo
Not Confirmed
arrow
Vietnam Medi-Pharm Expo
Not Confirmed
arrow

CAS Number : 116539-55-0

End Use API : Duloxetine Hydrochloride

About The Company : Chemeca Drugs Private Limited was erstwhile M/s. Vegesna Laboratories Pvt Limited. M/s. Vegesna Laboratories Pvt Limited is a Private limited company having its...

blank

10

Dasami Lab

India
Vietnam Medi-Pharm Expo
Not Confirmed
arrow

Dasami Lab

India
Vietnam Medi-Pharm Expo
Not Confirmed
arrow

CAS Number : 132335-44-5

End Use API : Duloxetine Hydrochloride

About The Company : Dasami Lab Private Limited incorporated with MCA on 24 July 2015. The Dasami Lab Private Limited is listed in the class of pvtltd company and classified as Non ...

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - CAPSULE, DELAYED REL PELLETS;ORAL - ...DOSAGE - CAPSULE, DELAYED REL PELLETS;ORAL - EQ 20MG BASE

USFDA APPLICATION NUMBER - 21427

read-more

DOSAGE - CAPSULE, DELAYED REL PELLETS;ORAL - ...DOSAGE - CAPSULE, DELAYED REL PELLETS;ORAL - EQ 30MG BASE

USFDA APPLICATION NUMBER - 21427

read-more

DOSAGE - CAPSULE, DELAYED REL PELLETS;ORAL - ...DOSAGE - CAPSULE, DELAYED REL PELLETS;ORAL - EQ 60MG BASE

USFDA APPLICATION NUMBER - 21427

read-more

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Coating Systems & Additives

read-more
read-more
click full view

Fillers, Diluents & Binders

read-more
read-more

Solubilizers

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Direct Compression

read-more
read-more

Controlled & Modified Release

read-more
read-more

Granulation

read-more
read-more
click full view

Thickeners and Stabilizers

read-more
read-more

Topical

read-more
read-more

Taste Masking

read-more
read-more

Parenteral

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Lubricants & Glidants

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Co-Processed Excipients

read-more
read-more

Emulsifying Agents

read-more
read-more

Empty Capsules

read-more
read-more

API Stability Enhancers

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Vegetarian Capsules

read-more
read-more

Rheology Modifiers

read-more
read-more

Coloring Agents

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ANALYTICAL

Upload your methods for free, ask us

ABOUT THIS PAGE

Looking for 136434-34-9 / Duloxetine Hydrochloride API manufacturers, exporters & distributors?

Duloxetine Hydrochloride manufacturers, exporters & distributors 1

84

PharmaCompass offers a list of Duloxetine Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Duloxetine Hydrochloride manufacturer or Duloxetine Hydrochloride supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Duloxetine Hydrochloride manufacturer or Duloxetine Hydrochloride supplier.

API | Excipient name

Duloxetine Hydrochloride

Synonyms

136434-34-9, Duloxetine hcl, Cymbalta, (s)-duloxetine hydrochloride, Ariclaim, Xeristar

Cas Number

136434-34-9

Unique Ingredient Identifier (UNII)

9044SC542W

About Duloxetine Hydrochloride

A thiophene derivative and selective NEUROTRANSMITTER UPTAKE INHIBITOR for SEROTONIN and NORADRENALINE (SNRI). It is an ANTIDEPRESSIVE AGENT and ANXIOLYTIC, and is also used for the treatment of pain in patients with DIABETES MELLITUS and FIBROMYALGIA.

Duloxetine hydrochloride- Bio-X Manufacturers

A Duloxetine hydrochloride- Bio-X manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Duloxetine hydrochloride- Bio-X, including repackagers and relabelers. The FDA regulates Duloxetine hydrochloride- Bio-X manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Duloxetine hydrochloride- Bio-X API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Duloxetine hydrochloride- Bio-X manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Duloxetine hydrochloride- Bio-X Suppliers

A Duloxetine hydrochloride- Bio-X supplier is an individual or a company that provides Duloxetine hydrochloride- Bio-X active pharmaceutical ingredient (API) or Duloxetine hydrochloride- Bio-X finished formulations upon request. The Duloxetine hydrochloride- Bio-X suppliers may include Duloxetine hydrochloride- Bio-X API manufacturers, exporters, distributors and traders.

click here to find a list of Duloxetine hydrochloride- Bio-X suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Duloxetine hydrochloride- Bio-X USDMF

A Duloxetine hydrochloride- Bio-X DMF (Drug Master File) is a document detailing the whole manufacturing process of Duloxetine hydrochloride- Bio-X active pharmaceutical ingredient (API) in detail. Different forms of Duloxetine hydrochloride- Bio-X DMFs exist exist since differing nations have different regulations, such as Duloxetine hydrochloride- Bio-X USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Duloxetine hydrochloride- Bio-X DMF submitted to regulatory agencies in the US is known as a USDMF. Duloxetine hydrochloride- Bio-X USDMF includes data on Duloxetine hydrochloride- Bio-X's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Duloxetine hydrochloride- Bio-X USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Duloxetine hydrochloride- Bio-X suppliers with USDMF on PharmaCompass.

Duloxetine hydrochloride- Bio-X JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The Duloxetine hydrochloride- Bio-X Drug Master File in Japan (Duloxetine hydrochloride- Bio-X JDMF) empowers Duloxetine hydrochloride- Bio-X API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the Duloxetine hydrochloride- Bio-X JDMF during the approval evaluation for pharmaceutical products. At the time of Duloxetine hydrochloride- Bio-X JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of Duloxetine hydrochloride- Bio-X suppliers with JDMF on PharmaCompass.

Duloxetine hydrochloride- Bio-X KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Duloxetine hydrochloride- Bio-X Drug Master File in Korea (Duloxetine hydrochloride- Bio-X KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Duloxetine hydrochloride- Bio-X. The MFDS reviews the Duloxetine hydrochloride- Bio-X KDMF as part of the drug registration process and uses the information provided in the Duloxetine hydrochloride- Bio-X KDMF to evaluate the safety and efficacy of the drug.

After submitting a Duloxetine hydrochloride- Bio-X KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Duloxetine hydrochloride- Bio-X API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Duloxetine hydrochloride- Bio-X suppliers with KDMF on PharmaCompass.

Duloxetine hydrochloride- Bio-X CEP

A Duloxetine hydrochloride- Bio-X CEP of the European Pharmacopoeia monograph is often referred to as a Duloxetine hydrochloride- Bio-X Certificate of Suitability (COS). The purpose of a Duloxetine hydrochloride- Bio-X CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Duloxetine hydrochloride- Bio-X EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Duloxetine hydrochloride- Bio-X to their clients by showing that a Duloxetine hydrochloride- Bio-X CEP has been issued for it. The manufacturer submits a Duloxetine hydrochloride- Bio-X CEP (COS) as part of the market authorization procedure, and it takes on the role of a Duloxetine hydrochloride- Bio-X CEP holder for the record. Additionally, the data presented in the Duloxetine hydrochloride- Bio-X CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Duloxetine hydrochloride- Bio-X DMF.

A Duloxetine hydrochloride- Bio-X CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Duloxetine hydrochloride- Bio-X CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

click here to find a list of Duloxetine hydrochloride- Bio-X suppliers with CEP (COS) on PharmaCompass.

Duloxetine hydrochloride- Bio-X WC

A Duloxetine hydrochloride- Bio-X written confirmation (Duloxetine hydrochloride- Bio-X WC) is an official document issued by a regulatory agency to a Duloxetine hydrochloride- Bio-X manufacturer, verifying that the manufacturing facility of a Duloxetine hydrochloride- Bio-X active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Duloxetine hydrochloride- Bio-X APIs or Duloxetine hydrochloride- Bio-X finished pharmaceutical products to another nation, regulatory agencies frequently require a Duloxetine hydrochloride- Bio-X WC (written confirmation) as part of the regulatory process.

click here to find a list of Duloxetine hydrochloride- Bio-X suppliers with Written Confirmation (WC) on PharmaCompass.

Duloxetine hydrochloride- Bio-X NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Duloxetine hydrochloride- Bio-X as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Duloxetine hydrochloride- Bio-X API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Duloxetine hydrochloride- Bio-X as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Duloxetine hydrochloride- Bio-X and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Duloxetine hydrochloride- Bio-X NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Duloxetine hydrochloride- Bio-X suppliers with NDC on PharmaCompass.

Duloxetine hydrochloride- Bio-X GMP

Duloxetine hydrochloride- Bio-X Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Duloxetine hydrochloride- Bio-X GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Duloxetine hydrochloride- Bio-X GMP manufacturer or Duloxetine hydrochloride- Bio-X GMP API supplier for your needs.

Duloxetine hydrochloride- Bio-X CoA

A Duloxetine hydrochloride- Bio-X CoA (Certificate of Analysis) is a formal document that attests to Duloxetine hydrochloride- Bio-X's compliance with Duloxetine hydrochloride- Bio-X specifications and serves as a tool for batch-level quality control.

Duloxetine hydrochloride- Bio-X CoA mostly includes findings from lab analyses of a specific batch. For each Duloxetine hydrochloride- Bio-X CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Duloxetine hydrochloride- Bio-X may be tested according to a variety of international standards, such as European Pharmacopoeia (Duloxetine hydrochloride- Bio-X EP), Duloxetine hydrochloride- Bio-X JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Duloxetine hydrochloride- Bio-X USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty